Related Experiment Video
Updated: Mar 3, 2026
Synthesis of 68Ga Core-doped Iron Oxide Nanoparticles for Dual Positron Emission Tomography /T1Magnetic Resonance Imaging
Published on: November 20, 2018
Somatostatin receptor-targeted organometallic iridium(iii) complexes as novel theranostic agents
Vojtech Novohradsky1, Ana Zamora, Albert Gandioso
1Institute of Biophysics, Academy of Sciences of the Czech Republic, v.v.i. Kralovopolska 135, 612 65 Brno, Czech Republic. brabec@ibp.cz.
Abstract:
A novel somatostatin receptor-targeted anticancer agent based on the conjugation of a highly cytotoxic and luminescent cyclometalated iridium(iii) complex to tumor-targeting vectors based on octreotide peptide has been described, and its potential for targeted theranostic applications has been demonstrated.
Insights
Researchers developed a new anticancer drug by linking a potent iridium(III) complex to octreotide peptides. This targeted agent shows promise for cancer theranostics, combining treatment and diagnosis.
Area of Science:
- Medicinal Chemistry
- Nanotechnology
- Oncology
Background:
- Somatostatin receptor (SSTR) targeted therapies are crucial for treating various cancers.
- Developing agents with both therapeutic and diagnostic capabilities (theranostics) is a significant goal in oncology.
Purpose of the Study:
- To design and synthesize a novel somatostatin receptor-targeted anticancer agent.
- To evaluate the potential of this agent for targeted theranostic applications in cancer treatment.
Main Methods:
- Conjugation of a cyclometalated iridium(III) complex with high cytotoxicity and luminescence.
- Utilizing octreotide peptide as a tumor-targeting vector for SSTR-positive tumors.
- Demonstration of theranostic potential through in vitro and/or in vivo studies (details not specified in abstract).
Main Results:
- Successful synthesis of a novel iridium(III)-octreotide conjugate.
- The conjugate exhibits potent anticancer activity.
- The luminescent properties of the iridium(III) complex enable potential diagnostic imaging.
Conclusions:
- A novel SSTR-targeted theranostic agent based on an iridium(III) complex and octreotide has been developed.
- This agent holds significant promise for targeted cancer therapy and diagnostics.
- Further studies are warranted to fully elucidate its clinical potential.
